Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Antibiotic prophylaxis with azithromycin in individuals with primary antibody deficiencies (PAD) may lead to a reduced risk of respiratory exacerbations, according to a phase II trial presented at ERS 2019.
Treatment without antibiotic medication does not appear to be inferior to moxifloxacin therapy as regards treatment failure or length of stay (LOS) among patients with chronic obstructive pulmonary disease (COPD) requiring hospitalization for nonpurulent exacerbation, according to the results of a study presented at the European Respiratory Society (ERS) International Congress 2019.
The PD-1* inhibitor nivolumab showed significant survival benefit and a favourable safety profile than taxane chemotherapy in patients with unresectable advanced or recurrent oesophageal squamous cell carcinoma (OSCC) refractory or intolerant to previous fluoropyrimidine- and platinum-based chemotherapy, according to the findings of ATTRACTION-3** presented at ESMO 2019.
New drug applications approved by US FDA as of 01 - 15 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
About one-third of patients with severe asthma who are on high-dose inhaled corticosteroids (ICS) are also receiving excessive doses of oral corticosteroids (OCS), reveals a study presented at the ERS 2019 Meeting.
A combination of the CDK 4/6 inhibitor abemaciclib with fulvestrant improved overall survival (OS) in patients with HR+, HER2- advanced breast cancer (ABC), with a trend toward improved outcomes in patients with poor prognosis, according to results of the phase III MONARCH 2* trial presented at ESMO 2019.
A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
The combination of sofosbuvir and velpatasvir is safe and effective for the treatment of hepatitis C virus (HCV) in patients with end-stage renal disease (ESRD) undergoing haemodialysis, a study has shown.